Gamma Inulin |
|
Vaxjo ID |
50 |
|
Vaccine Adjuvant Name |
Gamma Inulin |
|
Adjuvant VO ID |
VO_0001292
|
|
Description |
Gamma Inulin is a highly specific activator of the alternative pathway of complement in vitro and in vivo. Included in adjuvant formulations as a primary adjuvant and also as the immune stimulant when combined as composite particles with alum in the adjuvant Algammulin (Vogel and Powell, 1995). |
|
Stage of Development |
Clinical Trial |
|
Components |
Linear (unbranched) b-D-(2-1) polyfructofuranosyl-a-D-glucose, as particles in the gamma polymorphic configuration (Vogel and Powell, 1995). |
|
Preparation |
Obtained by aqueous extraction and crystallization of inulin, followed by adsorptive treatments, recrystallization and conversion to the gamma form at 37° C (Vogel and Powell, 1995). |
|
Function |
Expected to stimulate immune responses by causing ligation of leukocyte-surface complement receptors (CR) via known biochemical mechanisms. Addition of gamma inulin is known to enhance both humoral and cell-mediated immunity from both Thl and Th2 pathways. Gamma inulin also has an antitumor action and an effect on natural immunity (Vogel and Powell, 1995). |
|
Safety |
Nonpyrogenic, nonantigenic and of very low toxicity in experimental animals, Biodegradable to simple sugars. Large intravenous doses can cause acute complement-activation shock similar to that sometimes found in human renal dialysis patients. Dissolved inulin is pharmacologically inert and is registered for human use (Vogel and Powell, 1995). |
| Related Vaccine(s) |
|
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
